Imatinib
Thyroid Cancer
M.D. Anderson Cancer CenterSmall moleculePhase 1/2Dormant
CC
45/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 33/ 100
- Competitive Position
- 81/ 100
Competitive context
42 Active assets in the Thyroid Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Pembrolizumab Kineta Inc. | Phase 2 | BB |
ALECTINIB Hoffmann-La Roche | Phase 2 | B |
Denosumab Amgen | Phase 2 | B |
Sorafenib National Cancer Institute (NCI) | Phase 2 | B |
[18f]f-resca-rt4 RenJi Hospital | Phase 2/3 | CCC |
View all 50 →
Same molecule, other indications
Imatinib is also rated in:
blast phase chronic myelogenous leukemia, BCR-ABL1 positiveDormant
BB
Indicative ·
71 / 100
View asset →B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2)Dormant
BB
Indicative ·
69 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →